NASDAQ · PODD · Medical Devices
Insulet Corporation (PODD) stock analysis
- PODD gained 1.8% over the past month versus 0.0% for the S&P 500, ranking 279th of 497 S&P 500 stocks.
- Over 12 months it returned −56.6%, 72.4 points behind the S&P 500, and trades 59.0% below its 52-week high.
- In the last 30 days 1 analyst raised earnings estimates and 2 cut; forward EPS moved +0.1% (−4.1% over 90 days).
- It sits in the Chronic care & home monitoring segment of the Medtech, Diagnostics & Care, where the 1-month median return is −0.7%.
- The daily chart reads Intermediate downtrend · Countertrend rally (since Oct 20, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 20, 2026
- Price and averages have mixed alignment
- EMA50 fell over the last ten sessions
7 occurrences in 10 years. The median move over the next 20 sessions was +6.9%, positive 71% of the time, against +0.9% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
22 analysts cover the stock
Where it sits in the supply chain
Medtech, Diagnostics & Care · Devices, supplies & tests
Sleep apnea, insulin pumps and continuous glucose monitors keep patients on devices and supplies at home; GLP-1 uptake and reimbursement shift demand.
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Themes
- MedTech3M rank 62 / 90
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.